medigraphic.com
ISSN 1527-3172 (Digital)

2020, Número 1

<< Anterior Siguiente >>

MEDICC Review 2020; 22 (1)


Role of Business Models in Funding the Biotech Industry:

Blanco-García E

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 11-16
Archivo PDF: 144.43 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018 Dec 6;36(12):1136–45.

  2. Evens R, Kaitin K. The evolution of biotechnology and its impact on health care. Health Aff (Millwood). 2015 Feb;34(2):210–9.

  3. Thakor RT, Anaya N, Zhang Y, Vilanilam C, Siah KW, Wong CH, et al. Just how good an investment is the biopharmaceutical sector? Nat Biotechnol. 2017 Dec;35(12):1149–57.

  4. Pisano GP. Can science be a business? Lessons from biotech. Harv Bus Rev. 2006 Oct;84(10):114–24, 150.

  5. Stern S. Incentives and focus in university and industrial research: the case of synthetic insulin. In: Rosenberg N, Gelijns AC, Dawkins H, editors. Sources of Medical Technology: Universities and Industry. Washington, DC: National Academy of Sciences; 1995. p. 157–88.

  6. Schiff L, Murray F. Biotechnology fi nancing dilemmas and the role of special purpose entities. Nat Biotechnol. 2004 Mar;22(3):271–7.

  7. Ford D, Nelsen B. The view beyond venture capital. Nat Biotechnol. 2014 Jan;32(1):15–23.

  8. EY.com. Biotechnology Report 2017. Beyond borders: staying the course [Internet]. London: Ernst &Young; 2017 [cited 2019 Mar 19]. 100 p. Available from: https://www.ey.com/Publica tion/vwLUAssets/ey-biotechnology-report-2017 -beyond-borders-staying-the-course/$FILE/ ey-biotechnology-report-2017-beyond-borders -staying-the-course.pdf

  9. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017 Nov 1;177(11):1569–75.

  10. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010 Mar;9(3):203–14.

  11. Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical development success rates 2006–2015. San Diego: Biomedtracker; 2016 Jun. 28 p.

  12. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019 Apr 1;20(2):273–86.

  13. Morrison C, Lähteenmäki R. Public biotech in 2017-the numbers. Nat Biotechnol. 2018 Jul 6;36(7):576–84.

  14. Morrison C, Lahteenmaki R. Public biotech 2018-the numbers. Nat Biotechnol. 2019 Jul;37(7):714–21.

  15. Huggett B. Bringing up baby. Nat Biotechnol. 2018 May 9;36(5):393–401.

  16. Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018 Jan 10;36(1):46–60.

  17. McCammon MG, Pio E, Barakat S, Vyakarnam S. Corporate venture capital and Cambridge. Nat Biotechnol. 2014 Oct;32(10):975–8.

  18. Times TNY. Roche Agrees to Buy Genentech for $46.8 Billion. The New York Times [Internet]. 2009 Mar 12 [cited 2019 Mar 19]; World Business. Available from: https://www.nytimes.com/2009/03/13/ business/worldbusiness/13drugs.html.

  19. Grupo de las Industrias Biotecnológica y Farmacéutica de Cuba. BioCubaFarma [Internet]. Havana: BioCubaFarma, c2019 [cited 2019 Jun 4]. Available from: https://www.biocubafarma.cu. Spanish.

  20. World Health Organization [Internet]. Geneva: World Helath Organization; c2019. Publications. Cuban experience with local production of medicines, technology transfer and improving access to health [Internet]. Geneva: World Helath Organization; 2015. 80 p. Available from: https://www .who.int/phi/publications/cuban_experience _local_prod_medstech_transfer/en/

  21. Ministry of Foreign Affairs (CU). Informe de Cuba sobre la Resolución 73/8 de la Asamblea General de las Naciones Unidas. “Necesidad de poner fi n al bloqueo económico, comercial y fi nanciero impuesto por los Estados Unidos de América contra Cuba”. Havana: Ministry of Foreign Affairs (CU); [Internet]. 2019 Jul [cited 2019 Nov 6]. Available from: http://www.minrex.gob.cu/sites/ default/files/2019-09/Cuba%20vs%20Bloqueo .pdf. Spanish.

  22. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries— a systematic review. Int J Equity Health. 2018 Mar 22;17(1):37.

  23. García R, Araujo DV. The regulation of biosimilars in Latin America. Curr Rheumatol Rep. 2016 Mar;18(3):16.

  24. Ben-Joseph O. Where the bodies lie. Nat Biotechnol. 2016 Sep 8;34(9):909–11.

  25. Nasdaq [Internet]. New York: Nasdaq; c2019. Markets Equillium prices IPO at $14, the low end of the range; 2018 Oct 12 [cited 2019 Jun 21]. Available from: https://www.nasdaq.com/article/ equillium-prices-ipo-at-14-the-low-end-of-the -range-cm1036324




2020     |     www.medigraphic.com